cancer blood test News
-
GRAIL Statement on President Biden’s Bold Initiative to Reignite the Cancer Moonshot
“We applaud President Biden for reigniting the Cancer Moonshot and highlighting the critical role of early detection in achieving the ambitious, but attainable, goal of reducing the cancer death rate by at least 50 percent in the next 25 years. Improving quality of life for patients and survivors, while addressing inequities in access to cancer screening, diagnostics and treatment is a ...
By Grail, Inc.
-
FDA grants Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test
Pennsylvania June 8th, 2020: The FDA has granted Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test. Seravue® is intended for use as an aid in the diagnosis of Hepatocellular Carcinoma (HCC), including early stage HCC, in patients with an elevated risk of developing HCC, in conjunction with ultrasound imaging or alone in ...
-
FDA grants Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test
Pennsylvania June 8th, 2020: The FDA has granted Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test. Seravue® is intended for use as an aid in the diagnosis of Hepatocellular Carcinoma (HCC), including early stage HCC, in patients with an elevated risk of developing HCC, in conjunction with ultrasound imaging or alone in ...
-
Cleveland Diagnostics Chief Medical Officer, Mark Stovsky, MD, Participates in Panel Discussion on Early Cancer Detection During Cleveland Clinic`s 2019 Medical Innovation Summit
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced that its chief medical officer, Mark Stovsky, MD, participated in an Impact Session at the 2019 Medical Innovation Summit organized by Cleveland Clinic. The Medical Innovation Summit, which is celebrating its 17th year, is covering a wide ...
-
GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today a partnership with Alignment Health Plan, a national Medicare Advantage health plan from Alignment Healthcare (NASDAQ: ALHC), to provide its Medicare Advantage members access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test. Based in Orange, ...
By Grail, Inc.
-
GRAIL Receives New York State Approval for Galleri Multi-Cancer Early Detection Blood Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced that the New York State Department of Health (NYSDOH) has approved Galleri™, GRAIL’s groundbreaking multi-cancer early detection blood test. With NYSDOH approval, Galleri is now available to residents in the state of New York by prescription to complement existing single cancer screening tests. ...
By Grail, Inc.
-
Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina
Lawsuit is Seen as an Attempt to Stifle Competition and Retaliate Against Guardant Health for Registering Concerns About the Antitrust Implications of Illumina’s Acquisition of Grail REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today provided the following statement regarding a lawsuit filed by Illumina that seeks to ...
-
GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Premier, Inc.’s PINC AI™, an advanced technology and services platform that provides artificial intelligence-enabled clinical performance improvement technologies, to support patient access to Galleri®, GRAIL’s groundbreaking multi-cancer early ...
By Grail, Inc.
-
Knight Cancer Institute at Oregon Health & Science University to Offer the Galleri® Multi-Cancer Early Detection Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced a collaboration with the Knight Cancer Institute at Oregon Health & Science University (OHSU) to offer Galleri®, GRAIL’s multi-cancer early detection (MCED) blood test. OHSU will provide patients access to Galleri via a pilot program to help find signals of cancer in earlier stages and advance ...
By Grail, Inc.
-
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered single digit ...
By Grail, Inc.
-
Glycotest™ HCC Panel Completes Successful Clinical Product Evaluation
Glycotest Inc., announced today that it successfully completed a clinical evaluation of its HCC Panel in China. In a blinded evaluation of 149 HCC patient and control samples, the HCC Panel achieved an AUROC of 0.97. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to ...
-
ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells
Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC). The ...
-
Glycotest™ Intellectual Property Portfolio Expanded by United Sates, European and Australian Patents
Glycotest, Inc. announced today that a European patent has been granted and additional United States and Australian patents have been allowed. Together these patents will extend protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver ...
-
Glycotest™ Announces Grant of Japanese Patent
Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for earlystage liver cancer—has been granted. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality ...
-
Glycotest Intellectual Property Portfolio Strengthened by Grant of Japanese Patent
Glycotest Inc., announced today that a Japanese patent has been granted that provides important protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and ...
-
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology
Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer PALO ALTO, Calif. & BARCELONA, Spain--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading ...
-
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
Prospective registrational study expected to enroll nearly 10,000 patients in 36 months REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate ...
-
Glycotest Innovator Joins the Medical University of South Carolina as the New SmartState Endowed Chair of Proteomic Biomarkers
Glycotest, Inc. innovator Professor Anand Mehta, a leader in the development of glycoproteomic technologies for the discovery of novel cancer biomarkers, joins the Medical University of South Carolina (MUSC) and Hollings Cancer Center, Charleston, SC, as the new SmartState Endowed Chair of Proteomic Biomarkers, the company announced today (see MUSC). Mehta, whose work has resulted in 79 ...
-
Thermo Fisher Scientific Introduces Oncomine Clinical Research Grant Program to Support Oncology and Reproductive Health Studies
Thermo Fisher Scientific today introduced the Oncomine Clinical Research Grant Program to support clinical research projects in oncology and reproductive health. The program aims to provide support for high-quality molecular profiling studies focused on the generation of data that may improve clinical outcomes for patients in the future. As part of an initial pilot focused on oncology, the ...
-
Cleveland Diagnostics Announces Publication of Real-World Study Demonstrating the Clinical Utility of IsoPSA for Prostate Cancer Risk Assessment
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today the publication of a large real-world clinical utility study in Urology Practice, a peer-reviewed journal of the American Urological Association. The study, led by Dr. Eric Klein, Emeritus Professor and Chair of the Glickman Urological ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you